Summary of RNS in layman terms13 Jun 2023 16:23
In simpler terms, the company has developed a program called the MDK mRNA, which they've tested on breast and liver cancer cells in laboratory conditions (in vitro). Their aim was to see if the program could slow the growth and spread (or migration) of these cancer cells, which could be an early indicator of whether it might prevent the spread of cancer in the body (metastasis).
The results of these laboratory tests were very positive, showing a significant decrease in both the growth and the spread of the cancer cells. However, it's important to note that these are still early findings and they've only been observed in a controlled lab environment, not in actual patients (clinical trials).
If these effects can be reproduced in clinical trials, the MDK mRNA Program could potentially be the first of its kind in cancer medicine, representing a significant breakthrough.
The company is planning to share these promising initial results at a major upcoming cancer conference.